Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

 Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Gilead and Galapagos NV Reports Filgotinib (JAK1i) achieve 1EP and 2EP in FINCH-2 P-III study for the Treatment of RA

Shots:

  • FINCH-2 trial assessing filgotinib administering qd (200/100mg) vs PBO in ratio (1:1:1) for 24 wks. in moderate-to-severe active RA patients, intolerant to bDMARDs
  • FINCH-2 results (N= ≥153): ACR20@12wk (66 vs 57.5 vs 31.1) & ACR20@24wk (69.4 vs 54.9 vs 34.5) whereas, ACR70@12wk (21.8 vs 14.4 vs 6.8), ACR70@24wk (32.0 vs 20.3 vs 8.1) & DAS28LDA@12 (40.8 vs 37.3 vs 15.5)
  • Filgotinib was well tolerated in FINCH-2 trial with no new safety issues and occurrence of serious adverse events (4.1 %, 5.2 % 3.4 %) in patients
  • Gilead and Galapagos globally collaborated for filgotinib’s development and commercialization. Several trials are assessing filgotinib, including P-III FINCH 2 trial for RA/other inflammatory diseases, the EQUATOR P-II for PA, the TORTUGA study for AS, the DIVERSITY P-III trial for Crohn’s disease and the P-III SELECTION trial for ulcerative colitis

Click here to read full press release/ article | Ref: Gilead | Image: Nikkei Asian

Shiwani Sharma

Shiwani Sharma is a Senior Editor at PharmaShots. She has in-depth knowledge of lifesciences industry including pharma and biotech sectors. She also covers news in field of Digital Health, Medtech and regulatory approvals from the US FDA, EU, and other global regulatory bodies in the industry. Additionally, she also writes Whitepapers, analysis reports, blogs on pharma and biotech industry. She is graduate in Biotechnology. She can be contacted on shiwani@pharmashots.com

Related post